QDENGA® (TAK-003) Dengue Vaccine Description 2022
Takeda's QDENGA® (TAK-003) (Dengue Tetravalent Vaccine [Live, Attenuated]) is a tetravalent dengue vaccine preventing dengue fever caused by any of the four serotypes of the dengue virus that causes dengue fever or Severe Dengue. QDENGA® is based on a live-attenuated dengue serotype two virus, which provides the genetic "backbone" for all four dengue serotypes. QDENGA is the only dengue vaccine approved for use in individuals regardless of previous dengue exposure and without needing pre-vaccination testing.
Takeda's current clinical development program for QDENGA consists of five Phase 3 trials. Phase 1 and 2 data in children and adolescents showed that TAK-003 induced immune responses against all four dengue serotypes in seropositive and seronegative participants. In addition, the vaccine was found to be generally safe and well-tolerated.
In a November 2019 study, Takeda's dengue vaccine candidate demonstrated protection against virologically confirmed dengue, the trial's primary endpoint, in children ages 4 to 16. The vaccine efficacy (VE) was 80.2% in the 12 months after the 2nd vaccine dose, administered three months after the 1st dose.
The Lancet published an article on March 17, 2020, safety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomized, placebo-controlled, phase 2 trial, which concluded saying 'TAK-003 elicited antibody responses against all four serotypes, which persisted to 48 months post-vaccination, regardless of baseline serostatus.'
On July 13, 2020, the Long-term safety and immunogenicity of a tetravalent dengue vaccine candidate in children and adults: a randomized, placebo-controlled, phase 2 study, found at Month 36, seropositivity rates were 97.3%, 98.7%, 88.0%, and 56.0% for DENV-1, -2, -3 and -4, respectively. Seropositivity rates varied significantly for DENV-4 according to serostatus at baseline (89.5% in seropositive versus 21.6% in seronegative). No vaccine-related SAEs were reported.
On March 25, 2021, the Company announced Takeda is participating in the EMA's first-ever parallel assessment of a medicinal product for use in the European Union and through the EU-M4all (previously Article 58) procedure for countries outside of the EU. In addition, on May 20, 2021, an audio review of Three Years Efficacy of Takeda's Tetravalent Dengue Vaccine Candidate was published. The journal Clinical Infectious Disease published an ACCEPTED MANUSCRIPT on October 4, 2021: Three years efficacy and safety of Takeda's dengue vaccine candidate (TAK-003). This study concluded 'That TAK-003 was efficacious against symptomatic dengue over three years. Efficacy declined over time but remained robust against hospitalized dengue.'
New long-term results announced on June 9, 2022, supplement previously published TIDES data that demonstrated the candidate vaccine met its primary endpoint of overall VE against VCD, with 80.2% efficacy at 12-month follow-up, as well as all secondary endpoints for which there were a sufficient number of dengue cases at 18-months follow-up, including 90.4% VE against hospitalized dengue. While the long-term follow-up for the primary two-dose series has been completed, the TIDES trial remains ongoing to evaluate the safety and efficacy of a booster dose.
On August 22, 2022, Takeda confirmed that QDENGA had been authorized in Indonesia. For more information, visit www.TakedaVaccines.com. QDENGA - Trademark Details: 2019-06-04.
Osaka-based Takeda Pharmaceutical Company Limited (TSE: 4502, NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discovering and delivering life-transforming treatments, guided by our commitment to patients, our people, and the planet in approximately 80 countries and regions. For more information, visit https://www.takeda.com.
QDENGA (TAK-003) Availability
The Indonesia National Agency for Drug and Food Control, Badan Pengawas Obat dan Makanan (BPOM) authorized QDENGA to prevent dengue disease caused by any serotype in individuals six to 45 years of age on August 22, 2022. BPOM issued a distribution permit for Qdenga to be used in Indonesia on September 9, 2022.
TAK-003 is currently undergoing regulatory review to avoid dengue disease in children and adults in the European Union and select dengue-endemic countries. Takeda intends to submit regulatory filings in Argentina, Brazil, Colombia, Malaysia, Mexico, Singapore, Sri Lanka, and Thailand.
QDENGA (TAK-003) Indication
The TAK-003 vaccine candidate prevents the Dengue virus caused by the four Dengue serotypes. Dengue is the fastest spreading mosquito-borne viral disease and is one of the World Health Organization's top 10 global health threats in 2019. Dengue is pandemic-prone, and outbreaks are observed in tropical and sub-tropical areas and have recently caused outbreaks in parts of the continental United States and Europe. Approximately half of the world now lives under the threat of dengue, which is estimated to cause 390 million infections, 500,000 hospitalizations, and 20,000 deaths globally each year.
On June 10, 2021, the NEJM reported, 'In 2019, a total of 413 dengue cases were probably imported to Florida, including 14 cases of severe dengue (3.4%), predominantly in the Miami area. In addition, most travel-associated patients reported recent travel to Cuba and were infected with dengue virus serotype 2 (DENV-2).
QDENGA (TAK-003) Dosage
In clinical studies, TAK-003 was given as a DV 0.5 mL subcutaneous injection on Day 1 and Day 90. The onset of protection was seen after the 1st dose, with 81% VE between the 1st and 2nd doses. Results Through 4.5 Years Conclude the Evaluation of the Primary Two-Dose Series of TAK-003.
QDENGA (TAK-003) Side Effects
The ongoing phase 3 study demonstrated rates of serious adverse events were 2.9% in the TAK-003 group and 3.5% in the placebo group during the continuing long-term follow-up (i.e., the second half of the three years following vaccination), but none were related. Therefore, no critical safety risks were identified.
QDENGA (TAK-003) News 2016 - 2022
September 29, 2022 - What Clinicians Need to Know about Dengue in the United States: Clinician Outreach and Communication Activity Call presentation.
September 8, 2022 - The peer-review Internation Journal of Infections Disease published a Review article: Epidemiology and costs of dengue in Malaysia: a systematic literature review. Conclusion: To appropriately mitigate and control dengue, it is critical to implement integrated strategies, including vaccination, to reduce the burden of dengue.
September 6, 2022 - The U.S. CDC issued a Watch - Level 1, Practice Usual Precautions, travel advisory for Asia and the Pacific Islands.
August 29, 2022 - The FT reported: that Gary Dubin, president of Takeda's global vaccine business, said the approval of Qdenga on August 22 is the first achieved outside of Japan by the Company for a vaccine and could generate up to $1.6bn in annual sales.
August 22, 2022 - Gary Dubin, president of Takeda's Vaccine Business Unit, announced, "We're proud to introduce QDENGA as a new dengue prevention tool to the people of Indonesia, and we will continue to work with additional regulatory agencies to make QDENGA available globally."
August 15, 2022 - Dengue is a risk in many parts of Central and South America, Mexico, and the Caribbean, says the U.S. CDC.
July 28, 2022 - Takeda announced data from the Phase 3 TIDES clinical trial were presented at the 8th Northern European Conference on Travel Medicine. TAK-003 is undergoing regulatory review in the European Union and select dengue-endemic countries, with decisions expected in FY2022.
June 9, 2022 - Takeda announced that TAK-003 prevented 84% of hospitalized dengue cases and 61% of symptomatic dengue cases, with no important safety risks identified, in the overall population, including both seropositive and seronegative individuals through 54 months after vaccination in the pivotal Phase 3 TIDES clinical trial.
May 16, 2022 - National Dengue Day is used to spread awareness of this vector-borne disease and how to prevent it in India.
December 16, 2021 - The JAMA Network published a Viewpoint: Vaccination for Dengue Prevention. Physicians practicing in dengue-endemic areas of US territories and affiliated states can take the first steps in promoting health equity by implementing screen-and-vaccinate programs among children 9 to 16 years old, while physicians in all areas should be aware of new tools and possibilities in the rapidly developing field of dengue prevention.
October 4, 2021 - Clinical Infectious Disease reported TAK-003 efficacy and safety in seronegative and seropositive participants. Its performance varies by serotype, with some decline in efficacy from first to second-year post-vaccination. This review found the cumulative efficacy after three years was 62% against virologically-confirmed dengue (VCD) and 83.6% against hospitalized VCD. Efficacy was 54.3% against VCD and 77.1% against hospitalized VCD in baseline seronegatives, 65% against VCD, and 86% against hospitalized VCD in seropositives. Efficacy against VCD during the third year declined to 44.7%, while efficacy against hospitalized VCD was sustained at 70.8%.
July 30, 2021 - Takeda said the European Medicines Agency had converted a previous accelerated review of Takeda's dengue vaccine, TAK-003, to standard assessment. As a result, the Company expects a decision next year instead of a potential approval by the end of 2022.
March 25, 2021 - Takeda announced that the European Medicines Agency (EMA) had accepted the Company's filing packages for its dengue vaccine candidate (TAK-003). Takeda participates in the EMA's first-ever parallel assessment of a medicinal product for use in the European Union (EU) and through the EU-M4all (previously Article 58) procedure for countries outside the EU. Additionally, Takeda stated it intended to submit regulatory filings in Argentina, Brazil, Colombia, Indonesia, Malaysia, Mexico, Singapore, Sri Lanka, and Thailand in 2021.
March 15, 2021 - Japan-based Takeda Pharmaceutical Company Limited announced a mutual agreement with IDT Biologika GmbH ("IDT"), a contract development and manufacturing organization, to utilize capacity at IDT previously reserved for Takeda's dengue vaccine candidate (TAK-003) to manufacture the single-shot COVID-19 vaccine developed by the Janssen Pharmaceutical Companies.
December 15, 2020 - Study: Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination. TAK-003 demonstrated continued benefit independent of baseline serostatus in reducing dengue with some decline in efficacy during the second year. Three-year data will be essential to see if efficacy stabilizes or declines further. Takeda's tetravalent dengue vaccine (TAK-003) continued to demonstrate benefit in reducing dengue independent of baseline serostatus up to 2 years after completing vaccination, with some decline in efficacy in the second year in 4–16-year-olds in dengue-endemic countries.
July 13, 2020 - The phase 2 trial demonstrated the persistence of neutralizing antibody titers against TAK-003 over three years in children and adults living in dengue-endemic countries, with limited contribution from natural infection. TAK-003 was well tolerated. At month 36, seropositivity rates were 97.3%, 98.7%, 88.0% and 56.0% for DENV-1, -2, -3 and -4, respectively. Seropositivity rates varied significantly for DENV-4 according to serostatus at baseline (89.5% in seropositives versus 21.6% in seronegatives). No vaccine-related SAEs were reported.
March 17, 2020 - The Lancet published the 'Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomized, placebo-controlled, phase 2 trial.
March 17, 2020 - Commentary published by The Lancet: Evaluate a tetravalent dengue vaccine by serostatus and serotype.
November 23, 2019 - Takeda presented 18-month data from the pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial of its dengue vaccine candidate (TAK-003) at the 68th American Society of Tropical Medicine and Hygiene.
November 6, 2019 - Takeda's Dengue Vaccine Candidate Demonstrates Protection in Children Ages Four to 16 Years, Regardless of Previous Dengue Exposure.
November 5, 2019 – Takeda Pharmaceutical Company announced its new manufacturing plant in Singen, Germany, for its dengue vaccine candidate, TAK-003.
January 29, 2019 - Takeda announced that TAK-003, which is in a pivotal Phase 3 trial, met the primary efficacy endpoint. This first analysis of the Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial showed that its investigational live-attenuated tetravalent dengue vaccine was efficacious in preventing dengue fever caused by any of the four serotypes of the virus. In addition, while the extensive data set review is ongoing, TAK-003 was well tolerated, with no significant safety concerns to date. The TIDES trial continues, and additional results are expected later this year, along with results from other Phase 3 studies.
October 31, 2018 - About dengue and Takeda's dengue vaccine candidate (TAK-003).
September 7, 2016 - Takeda Initiated the Global Phase 3 Clinical Trial (TIDES) of Dengue Vaccine Candidate (TAK-003).
QDENGA TAK-003 Clinical Trials
Takeda's investigational live-attenuated tetravalent dengue vaccine candidate, TAK-003, is studied in healthy children and adults in dengue-endemic and non-endemic countries. Its clinical development program consists of Phase III, Double-Blind, Randomized, Placebo-Controlled Trial to Investigate the Efficacy, Safety, and Immunogenicity of a Tetravalent Dengue Vaccine (TDV) Administered Subcutaneously in Healthy Children Aged 4 - 16 Years Old. The trial is taking place at sites in dengue-endemic areas in Latin America (Brazil, Colombia, Panama, the Dominican Republic, and Nicaragua) and Asia (Philippines, Thailand, and Sri Lanka).
As of June 9, 2022, through four and a half years, TAK-003 demonstrated 84.1% vaccine efficacy (VE) (95% CI: 77.8, 88.6) against hospitalized dengue, with 85.9% VE (78.7, 90.7) in seropositive individuals and 79.3% VE (63.5, 88.2) in seronegative individuals. TAK-003 also demonstrated overall VE of 61.2% (95% CI: 56.0, 65.8) against virologically-confirmed dengue (VCD), with 64.2% VE (58.4, 69.2) in seropositive individuals and 53.5% VE (41.6, 62.9) in seronegative individuals. Observations of VE varied by serotype and remained consistent with previously reported results. TAK-003 was generally well tolerated, and no important safety risks were identified. No evidence of disease enhancement was observed over the 54-month follow-up exploratory analysis.
These new long-term results supplement previously published TIDES data that demonstrated the candidate vaccine met its primary endpoint of overall VE against VCD, with 80.2% efficacy at 12-month follow-up, as well as all secondary endpoints for which there were a sufficient number of dengue cases at 18-months follow-up, including 90.4% VE against hospitalized dengue. While the long-term follow-up for the primary two-dose series has been completed, the TIDES trial remains ongoing to evaluate the safety and efficacy of a booster dose. The TIDES trial is Takeda's largest interventional clinical trial, enrolling more than 20,000 healthy children and adolescents four to 16 years of age, across eight dengue-endemic countries, over the past four and a half years.